Unlocking GIP Receptor Antagonism as an Amylin Sensitizer for Next Generation Cardiometabolic Therapy
9:30 am - Thursday 3rd December 2026
- Establish GIP receptor antagonism as a foundational cardiometabolic mechanism, exploring effects beyond appetite suppression and the potential for independent improvements across glycaemic control, lipid metabolism and body composition
- Demonstrate how GIPR antagonism can sensitize complementary nutrient-stimulated hormone pathways, examining the rationale for combining AT-7687 with GLP-1 and amylin-based therapies to enhance efficacy without compounding tolerability10.30 DACRA Debate
- Translate human genetics and preclinical combination evidence into an amylin strategy, leveraging data showing synergy between GIPR antagonism and dual amylin/calcitonin receptor agonism in translational models to inform rational nextgeneration combinations
